Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer
Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of metastatic progression in patients with high-risk prostate cancer. A retrospective matched case-control study of two clinico-pathologically iden...
Saved in:
Published in | Molecular cancer research Vol. 20; no. 4; pp. 527 - 541 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.04.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of metastatic progression in patients with high-risk prostate cancer. A retrospective matched case-control study of two clinico-pathologically identical groups of patients with high-risk prostate cancer was undertaken. One group developed metastatic recurrence (n = 19) while the other did not (n = 25). The primary index tumor was identified by a uro-pathologist, followed by DNA and RNA extraction for somatic copy-number aberration (SCNA) analysis and whole-transcriptome gene expression analysis. In vitro and in vivo studies included cell line manipulation and xenograft models.
The integrative CNA and gene expression analyses identified an increase in Antizyme Inhibitor 1 (AZIN1) gene expression within a focal amplification of 8q22.3, which was associated with metastatic recurrence of patients with high-risk prostate cancer in four independent cohorts. The effects of AZIN1 knockdown were evaluated, due to its therapeutic potential. AZIN1 knockdown effected proliferation and metastatic potential of prostate cancer cells and xenograft models. RNA sequencing after AZIN1 knockdown in prostate cancer cells revealed upregulation of genes coding for collagen subunits. The observed effect on cell migration after AZIN1 knockdown was mimicked when exposing prostate cancer cells to bio-active molecules deriving from COL4A1 and COL4A2. Our integrated CNA and gene expression analysis of primary high-risk prostate cancer identified the AZIN1 gene as a novel driver of metastatic progression, by altering collagen subunit expression. Future research should further investigate its therapeutic potential in preventing metastatic recurrence.
AZIN1 was identified as driver of metastatic progression in high-risk prostate cancer through matrikine regulation. |
---|---|
AbstractList | Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of metastatic progression in patients with high-risk prostate cancer. A retrospective matched case-control study of two clinico-pathologically identical groups of patients with high-risk prostate cancer was undertaken. One group developed metastatic recurrence (n = 19) while the other did not (n = 25). The primary index tumor was identified by a uro-pathologist, followed by DNA and RNA extraction for somatic copy-number aberration (SCNA) analysis and whole-transcriptome gene expression analysis. In vitro and in vivo studies included cell line manipulation and xenograft models. The integrative CNA and gene expression analyses identified an increase in Antizyme Inhibitor 1 (AZIN1) gene expression within a focal amplification of 8q22.3, which was associated with metastatic recurrence of patients with high-risk prostate cancer in four independent cohorts. The effects of AZIN1 knockdown were evaluated, due to its therapeutic potential. AZIN1 knockdown effected proliferation and metastatic potential of prostate cancer cells and xenograft models. RNA sequencing after AZIN1 knockdown in prostate cancer cells revealed upregulation of genes coding for collagen subunits. The observed effect on cell migration after AZIN1 knockdown was mimicked when exposing prostate cancer cells to bio-active molecules deriving from COL4A1 and COL4A2. Our integrated CNA and gene expression analysis of primary high-risk prostate cancer identified the AZIN1 gene as a novel driver of metastatic progression, by altering collagen subunit expression. Future research should further investigate its therapeutic potential in preventing metastatic recurrence. IMPLICATIONSAZIN1 was identified as driver of metastatic progression in high-risk prostate cancer through matrikine regulation. Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of metastatic progression in patients with high-risk prostate cancer. A retrospective matched case-control study of two clinico-pathologically identical groups of patients with high-risk prostate cancer was undertaken. One group developed metastatic recurrence (n = 19) while the other did not (n = 25). The primary index tumor was identified by a uro-pathologist, followed by DNA and RNA extraction for somatic copy-number aberration (SCNA) analysis and whole-transcriptome gene expression analysis. In vitro and in vivo studies included cell line manipulation and xenograft models. The integrative CNA and gene expression analyses identified an increase in Antizyme Inhibitor 1 (AZIN1) gene expression within a focal amplification of 8q22.3, which was associated with metastatic recurrence of patients with high-risk prostate cancer in four independent cohorts. The effects of AZIN1 knockdown were evaluated, due to its therapeutic potential. AZIN1 knockdown effected proliferation and metastatic potential of prostate cancer cells and xenograft models. RNA sequencing after AZIN1 knockdown in prostate cancer cells revealed upregulation of genes coding for collagen subunits. The observed effect on cell migration after AZIN1 knockdown was mimicked when exposing prostate cancer cells to bio-active molecules deriving from COL4A1 and COL4A2. Our integrated CNA and gene expression analysis of primary high-risk prostate cancer identified the AZIN1 gene as a novel driver of metastatic progression, by altering collagen subunit expression. Future research should further investigate its therapeutic potential in preventing metastatic recurrence. AZIN1 was identified as driver of metastatic progression in high-risk prostate cancer through matrikine regulation. |
Author | Boeckx, Bram Ghesquière, Bart Karnes, R Jeffrey Moris, Lisa Claessens, Frank Lotan, Tamara Helsen, Christine El Kharraz, Sarah Van den Broeck, Thomas Devlies, Wout Handle, Florian Davicioni, Elai Van Poppel, Hendrik Eerlings, Roy Gevaert, Thomas Soenen, Stefaan Smeets, Elien Lambrechts, Diether Joniau, Steven |
Author_xml | – sequence: 1 givenname: Thomas surname: Van den Broeck fullname: Van den Broeck, Thomas organization: Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium – sequence: 2 givenname: Lisa surname: Moris fullname: Moris, Lisa organization: Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium – sequence: 3 givenname: Thomas surname: Gevaert fullname: Gevaert, Thomas organization: Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium – sequence: 4 givenname: Elai orcidid: 0000-0001-9136-099X surname: Davicioni fullname: Davicioni, Elai organization: Research and Development, Decipher Biosciences, San Diego, California – sequence: 5 givenname: Bram surname: Boeckx fullname: Boeckx, Bram organization: Laboratory of Translational Genetics, VIB-KU Leuven, Department of Human Genetics, Biomedical Sciences Group, KU Leuven, Leuven, Belgium – sequence: 6 givenname: Diether orcidid: 0000-0002-3429-302X surname: Lambrechts fullname: Lambrechts, Diether organization: Laboratory of Translational Genetics, VIB-KU Leuven, Department of Human Genetics, Biomedical Sciences Group, KU Leuven, Leuven, Belgium – sequence: 7 givenname: Christine orcidid: 0000-0003-1048-2798 surname: Helsen fullname: Helsen, Christine organization: Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium – sequence: 8 givenname: Florian orcidid: 0000-0002-7558-5635 surname: Handle fullname: Handle, Florian organization: Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium – sequence: 9 givenname: Bart orcidid: 0000-0003-1547-1705 surname: Ghesquière fullname: Ghesquière, Bart organization: Metabolomics Core, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium – sequence: 10 givenname: Stefaan surname: Soenen fullname: Soenen, Stefaan organization: NanoHealth and Optical Imaging Group, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Biomedical Sciences Group, KU Leuven, Leuven, Belgium – sequence: 11 givenname: Elien surname: Smeets fullname: Smeets, Elien organization: Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium – sequence: 12 givenname: Roy orcidid: 0000-0001-9661-8312 surname: Eerlings fullname: Eerlings, Roy organization: Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium – sequence: 13 givenname: Sarah orcidid: 0000-0003-1444-2531 surname: El Kharraz fullname: El Kharraz, Sarah organization: Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium – sequence: 14 givenname: Wout surname: Devlies fullname: Devlies, Wout organization: Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium – sequence: 15 givenname: R Jeffrey surname: Karnes fullname: Karnes, R Jeffrey organization: Department of Urology, Mayo Clinic, Rochester, Minnesota – sequence: 16 givenname: Tamara surname: Lotan fullname: Lotan, Tamara organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland – sequence: 17 givenname: Hendrik surname: Van Poppel fullname: Van Poppel, Hendrik organization: Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium – sequence: 18 givenname: Steven orcidid: 0000-0003-3195-9890 surname: Joniau fullname: Joniau, Steven organization: Department of Urology, University Hospitals Leuven, KU Leuven, Leuven, Belgium – sequence: 19 givenname: Frank orcidid: 0000-0002-8676-7709 surname: Claessens fullname: Claessens, Frank organization: Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35082164$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kMtOAjEUhhuDkYs-gqZLN4O9TGc6S0JQSSASouumdM5AdejgtBhx46s7I-jqnMX3n8vXRx1XOUDompIhpULeURHTKE1lMpyPlxGjEeFSnqEeFSKNOGWi0_Ynpov63r8SwghNkwvU5YJIRpO4h75HLtivwxbw1G3syoaqxhQvYb0vdQCP5zrU9s06wJPPXQ3e28ph7XI8cRvtTEOEDeA5BO2DDtbgRRWgGalLXBV4tF7_Zj4AL2q71fWhqVVLAh638foSnRe69HB1qgP0cj95Hj9Gs6eH6Xg0iwwXSYgSLoVMpclWiVkJkgmSi4QWJk-br0EYY4pYZpzlGZEQC80Y07mUgvOMShYTPkC3x7m7unrfgw9qa72BstQOqr1XLGGcMyEJbVBxRE1zqq-hULvj7YoS1bpXrVfVelWNe8Woat03uZvTiv1qC_l_6k82_wGz1IJh |
CitedBy_id | crossref_primary_10_3390_biomedicines11072006 crossref_primary_10_1016_j_eururo_2023_05_033 crossref_primary_10_1186_s12964_023_01445_1 |
Cites_doi | 10.1007/s00428-018-2450-x 10.1016/j.cell.2011.09.024 10.1371/journal.pone.0066855 10.1016/S1470-2045(10)70295-3 10.1016/j.eururo.2014.10.036 10.1016/j.ccr.2010.05.026 10.2147/OTT.S281157 10.1002/ijc.32430 10.3390/ijms21031078 10.1073/pnas.1411446111 10.1016/j.ijrobp.2015.07.320 10.1093/bib/bbq086 10.1016/j.humpath.2017.08.036 10.21147/j.issn.1000-9604.2019.06.08 10.1080/19336918.2016.1212139 10.1016/j.critrevonc.2003.06.007 10.1042/bse0460004 10.1074/jbc.M407349200 10.1158/1055-9965.EPI-07-0658 10.1016/j.juro.2013.06.017 10.1242/jcs.02966 10.1158/0008-5472.CAN-04-3536 10.1172/JCI23412 10.1038/nrurol.2018.22 10.1158/1078-0432.CCR-12-3791 10.1074/jbc.M410234200 10.1038/nrc1454 10.1016/j.ygeno.2012.08.003 10.1200/JCO.2007.15.6752 10.1016/j.ajpath.2011.03.008 10.1186/s12885-017-3729-z 10.1016/j.eururo.2020.09.042 10.1097/PAS.0000000000000208 10.1593/neo.05664 10.1016/j.euo.2018.12.007 10.1038/nature09744 10.1158/1078-0432.CCR-19-1587 10.1016/j.celrep.2018.10.093 10.1016/j.cell.2013.03.021 10.1016/j.ygeno.2007.02.005 10.1038/ng1935 10.1016/j.bbagen.2013.12.029 10.1074/jbc.M307339200 10.1016/B978-0-12-817068-7.00033-1 10.1016/j.eururo.2014.01.020 10.1038/nbt.2203 10.1158/2159-8290.CD-12-0095 10.1083/jcb.95.1.340 10.1016/j.devcel.2018.05.033 10.1016/j.ajpath.2012.08.005 10.1111/cas.13122 |
ContentType | Journal Article |
Copyright | 2022 American Association for Cancer Research. |
Copyright_xml | – notice: 2022 American Association for Cancer Research. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1158/1541-7786.MCR-21-0388 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1557-3125 |
EndPage | 541 |
ExternalDocumentID | 10_1158_1541_7786_MCR_21_0388 35082164 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 123 18M 2FS 2WC 34G 39C 53G 5RE 5VS ACGFO ACPRK ADBBV ADCOW AENEX AFHIN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 HH5 IH2 KQ8 L7B NPM OK1 QTD RCR RHF RHI TR2 W8F WOQ YKV AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c356t-6385878c9b6cb50950d561fcd7388e5cccf48932d908e45a222ad885339182403 |
ISSN | 1541-7786 |
IngestDate | Thu Jul 25 09:48:39 EDT 2024 Thu Nov 21 21:09:32 EST 2024 Sat Sep 28 08:19:18 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | 2022 American Association for Cancer Research. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c356t-6385878c9b6cb50950d561fcd7388e5cccf48932d908e45a222ad885339182403 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-9136-099X 0000-0003-3195-9890 0000-0001-9661-8312 0000-0002-7558-5635 0000-0003-1547-1705 0000-0002-8676-7709 0000-0003-1444-2531 0000-0003-1048-2798 0000-0002-3429-302X |
OpenAccessLink | https://lirias.kuleuven.be/bitstream/20.500.12942/689435/2/Vandenbroeck%20et%20al%2c%20Mol%20Cancer%20Res%202022.pdf |
PMID | 35082164 |
PQID | 2623325801 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_2623325801 crossref_primary_10_1158_1541_7786_MCR_21_0388 pubmed_primary_35082164 |
PublicationCentury | 2000 |
PublicationDate | 2022-04-01 20220401 |
PublicationDateYYYYMMDD | 2022-04-01 |
PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular cancer research |
PublicationTitleAlternate | Mol Cancer Res |
PublicationYear | 2022 |
References | Colorado (2022060712151366500_bib41) 2000; 60 Monboisse (2022060712151366500_bib40) 2014; 1840 Simbolo (2022060712151366500_bib26) 2018; 473 Meyskens (2022060712151366500_bib38) 1999; 5 Taylor (2022060712151366500_bib5) 2010; 18 Sinha (2022060712151366500_bib25) 2018; 73 Klein (2022060712151366500_bib18) 2015; 67 Kahana (2022060712151366500_bib32) 2009; 46 Wang (2022060712151366500_bib27) 2019; 31 Bibikova (2022060712151366500_bib50) 2007; 89 Tomlins (2022060712151366500_bib4) 2007; 39 Spratt (2022060712151366500_bib13) 2019; 25 Cuzick (2022060712151366500_bib48) 2011; 12 Erho (2022060712151366500_bib17) 2013; 8 Reese-Petersen (2022060712151366500_bib43) 2019 Bismar (2022060712151366500_bib49) 2006; 8 Long (2022060712151366500_bib47) 2011; 179 Kim (2022060712151366500_bib34) 2006; 119 Lo (2022060712151366500_bib23) 2018; 45 Simoneau (2022060712151366500_bib37) 2008; 17 Maquart (2022060712151366500_bib42) 2004; 49 Aparicio (2022060712151366500_bib28) 2013; 19 Tulluri (2022060712151366500_bib36) 2021; 14 Joshi (2022060712151366500_bib46) 2017; 11 Piccolo (2022060712151366500_bib12) 2012; 100 Baca (2022060712151366500_bib7) 2013; 153 Gao (2022060712151366500_bib21) 2014; 6 Carter (2022060712151366500_bib10) 2012; 30 Zhu (2022060712151366500_bib35) 2018; 25 Qiu (2022060712151366500_bib9) 2017; 108 Hieronymus (2022060712151366500_bib30) 2014; 111 Bercovich (2022060712151366500_bib31) 2004; 279 Valastyan (2022060712151366500_bib3) 2011; 147 Laurie (2022060712151366500_bib39) 1982; 95 Cerami (2022060712151366500_bib22) 2012; 2 Panka (2022060712151366500_bib44) 2003; 278 Berger (2022060712151366500_bib6) 2011; 470 Alshalalfa (2022060712151366500_bib14) 2019; 145 Davies (2022060712151366500_bib24) 2018; 15 Magnon (2022060712151366500_bib45) 2005; 65 Joniau (2022060712151366500_bib1) 2015; 67 Glinsky (2022060712151366500_bib54) 2005; 115 Lockstone (2022060712151366500_bib11) 2011; 12 Ostano (2022060712151366500_bib15) 2020; 21 Van den Broeck (2022060712151366500_bib52) 2019; 2 Cheville (2022060712151366500_bib53) 2008; 26 Mottet (2022060712151366500_bib2) 2021; 79 Tsai (2022060712151366500_bib16) 2017; 17 Karnes (2022060712151366500_bib19) 2013; 190 Newman (2022060712151366500_bib33) 2004; 279 Den (2022060712151366500_bib20) 2015; 93 Epstein (2022060712151366500_bib29) 2014; 38 Gerner (2022060712151366500_bib8) 2004; 4 Agell (2022060712151366500_bib51) 2012; 181 |
References_xml | – volume: 473 start-page: 709 year: 2018 ident: 2022060712151366500_bib26 article-title: Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine publication-title: Virchows Arch doi: 10.1007/s00428-018-2450-x contributor: fullname: Simbolo – volume: 147 start-page: 275 year: 2011 ident: 2022060712151366500_bib3 article-title: Tumor metastasis: molecular insights and evolving paradigms the invasion-metastasis cascade publication-title: Cell doi: 10.1016/j.cell.2011.09.024 contributor: fullname: Valastyan – volume: 8 start-page: e66855 year: 2013 ident: 2022060712151366500_bib17 article-title: Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy publication-title: PLoS One doi: 10.1371/journal.pone.0066855 contributor: fullname: Erho – volume: 12 start-page: 245 year: 2011 ident: 2022060712151366500_bib48 article-title: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes for recurrence and death from prostate cancer: a retrospective study in two cohorts publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70295-3 contributor: fullname: Cuzick – volume: 67 start-page: 778 year: 2015 ident: 2022060712151366500_bib18 article-title: A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy publication-title: Eur Urol doi: 10.1016/j.eururo.2014.10.036 contributor: fullname: Klein – volume: 18 start-page: 11 year: 2010 ident: 2022060712151366500_bib5 article-title: Integrative genomic profiling of human prostate cancer publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.05.026 contributor: fullname: Taylor – volume: 14 start-page: 667 year: 2021 ident: 2022060712151366500_bib36 article-title: Role of antizyme inhibitor proteins in cancers and beyond publication-title: Onco Targets Ther doi: 10.2147/OTT.S281157 contributor: fullname: Tulluri – volume: 145 start-page: 3453 year: 2019 ident: 2022060712151366500_bib14 article-title: Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma publication-title: Int J Cancer doi: 10.1002/ijc.32430 contributor: fullname: Alshalalfa – volume: 21 start-page: 1078 year: 2020 ident: 2022060712151366500_bib15 article-title: Gene expression signature predictive of neuroendocrine transformation in prostate adenocarcinoma publication-title: Int J Mol Sci doi: 10.3390/ijms21031078 contributor: fullname: Ostano – volume: 111 start-page: 11139 year: 2014 ident: 2022060712151366500_bib30 article-title: Copy number alteration burden predicts prostate cancer relapse publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1411446111 contributor: fullname: Hieronymus – volume: 93 start-page: S134 year: 2015 ident: 2022060712151366500_bib20 article-title: Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy publication-title: Int J Radiat Oncol doi: 10.1016/j.ijrobp.2015.07.320 contributor: fullname: Den – volume: 12 start-page: 634 year: 2011 ident: 2022060712151366500_bib11 article-title: Exon array data analysis using Affymetrix power tools and R statistical software publication-title: Brief Bioinform doi: 10.1093/bib/bbq086 contributor: fullname: Lockstone – volume: 73 start-page: 16 year: 2018 ident: 2022060712151366500_bib25 article-title: Characterization of genome-wide copy number aberrations in colonic mixed adenoneuroendocrine carcinoma and neuroendocrine carcinoma reveals recurrent amplification of PTGER4 and MYC genes publication-title: Hum Pathol doi: 10.1016/j.humpath.2017.08.036 contributor: fullname: Sinha – volume: 31 start-page: 918 year: 2019 ident: 2022060712151366500_bib27 article-title: Genomic dissection of gastrointestinal and lung neuroendocrine neoplasm publication-title: Chinese J Cancer Res doi: 10.21147/j.issn.1000-9604.2019.06.08 contributor: fullname: Wang – volume: 11 start-page: 305 year: 2017 ident: 2022060712151366500_bib46 article-title: Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the α5β1 integrin publication-title: Cell Adhes Migr doi: 10.1080/19336918.2016.1212139 contributor: fullname: Joshi – volume: 49 start-page: 199 year: 2004 ident: 2022060712151366500_bib42 article-title: An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity - implication in tumor invasion publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2003.06.007 contributor: fullname: Maquart – volume: 46 start-page: 47 year: 2009 ident: 2022060712151366500_bib32 article-title: Regulation of cellular polyamine levels and cellular proliferation by antizyme and antizyme inhibitor publication-title: Essays Biochem doi: 10.1042/bse0460004 contributor: fullname: Kahana – volume: 279 start-page: 41504 year: 2004 ident: 2022060712151366500_bib33 article-title: Antizyme targets cyclin D1 for degradation: A novel mechanism for cell growth repression publication-title: J Biol Chem doi: 10.1074/jbc.M407349200 contributor: fullname: Newman – volume: 17 start-page: 292 year: 2008 ident: 2022060712151366500_bib37 article-title: The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: Results of a year-long phase iib randomized placebo-controlled chemoprevention trial publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-07-0658 contributor: fullname: Simoneau – volume: 190 start-page: 2047 year: 2013 ident: 2022060712151366500_bib19 article-title: Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population publication-title: J Urol doi: 10.1016/j.juro.2013.06.017 contributor: fullname: Karnes – volume: 119 start-page: 2583 year: 2006 ident: 2022060712151366500_bib34 article-title: Regulation of cell proliferation by the antizyme inhibitor: Evidence for an antizyme-independent mechanism publication-title: J Cell Sci doi: 10.1242/jcs.02966 contributor: fullname: Kim – volume: 65 start-page: 5989 year: 2005 ident: 2022060712151366500_bib45 article-title: Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-3536 contributor: fullname: Magnon – volume: 115 start-page: 1503 year: 2005 ident: 2022060712151366500_bib54 article-title: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer publication-title: J Clin Invest doi: 10.1172/JCI23412 contributor: fullname: Glinsky – volume: 15 start-page: 271 year: 2018 ident: 2022060712151366500_bib24 article-title: Cellular plasticity and the neuroendocrine phenotype in prostate cancer publication-title: Nat Rev Urol doi: 10.1038/nrurol.2018.22 contributor: fullname: Davies – volume: 19 start-page: 3621 year: 2013 ident: 2022060712151366500_bib28 article-title: Platinum-based chemotherapy for variant castrate-resistant prostate cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3791 contributor: fullname: Aparicio – volume: 279 start-page: 54097 year: 2004 ident: 2022060712151366500_bib31 article-title: Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme publication-title: J Biol Chem doi: 10.1074/jbc.M410234200 contributor: fullname: Bercovich – volume: 4 start-page: 781 year: 2004 ident: 2022060712151366500_bib8 article-title: Polyamines and cancer: Old molecules, new understanding publication-title: Nat Rev Cancer doi: 10.1038/nrc1454 contributor: fullname: Gerner – volume: 100 start-page: 337 year: 2012 ident: 2022060712151366500_bib12 article-title: A single-sample microarray normalization method to facilitate personalized-medicine workflows publication-title: Genomics doi: 10.1016/j.ygeno.2012.08.003 contributor: fullname: Piccolo – volume: 26 start-page: 3930 year: 2008 ident: 2022060712151366500_bib53 article-title: Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.6752 contributor: fullname: Cheville – volume: 179 start-page: 46 year: 2011 ident: 2022060712151366500_bib47 article-title: Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy publication-title: Am J Pathol doi: 10.1016/j.ajpath.2011.03.008 contributor: fullname: Long – volume: 17 start-page: 1 year: 2017 ident: 2022060712151366500_bib16 article-title: Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma publication-title: BMC Cancer doi: 10.1186/s12885-017-3729-z contributor: fullname: Tsai – volume: 5 start-page: 945 year: 1999 ident: 2022060712151366500_bib38 article-title: Development of difluoromethylornithine (DFMO) as a chemoprevention agent publication-title: Clin Cancer Res contributor: fullname: Meyskens – volume: 79 start-page: 243 year: 2021 ident: 2022060712151366500_bib2 article-title: EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 update. part 1: Screening, diagnosis, and local treatment with curative intent publication-title: Eur Urol doi: 10.1016/j.eururo.2020.09.042 contributor: fullname: Mottet – volume: 38 start-page: 756 year: 2014 ident: 2022060712151366500_bib29 article-title: Proposed morphologic classification of prostate cancer with neuroendocrine differentiation publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000208 contributor: fullname: Epstein – volume: 8 start-page: 59 year: 2006 ident: 2022060712151366500_bib49 article-title: Defining aggressive prostate cancer using a 12-gene model publication-title: Neoplasia doi: 10.1593/neo.05664 contributor: fullname: Bismar – volume: 2 start-page: 589 year: 2019 ident: 2022060712151366500_bib52 article-title: Validation of the decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2018.12.007 contributor: fullname: Van den Broeck – volume: 470 start-page: 214 year: 2011 ident: 2022060712151366500_bib6 article-title: The genomic complexity of primary human prostate cancer publication-title: Nature doi: 10.1038/nature09744 contributor: fullname: Berger – volume: 25 start-page: 6721 year: 2019 ident: 2022060712151366500_bib13 article-title: Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naïve primary prostate cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-1587 contributor: fullname: Spratt – volume: 25 start-page: 2285 year: 2018 ident: 2022060712151366500_bib35 article-title: Single-cell transcriptome analysis reveals estrogen signaling coordinately augments one-carbon, polyamine, and purine synthesis in breast cancer publication-title: Cell Rep doi: 10.1016/j.celrep.2018.10.093 contributor: fullname: Zhu – volume: 153 start-page: 666 year: 2013 ident: 2022060712151366500_bib7 article-title: Punctuated evolution of prostate cancer genomes publication-title: Cell doi: 10.1016/j.cell.2013.03.021 contributor: fullname: Baca – volume: 89 start-page: 666 year: 2007 ident: 2022060712151366500_bib50 article-title: Expression signatures that correlated with Gleason score and relapse in prostate cancer publication-title: Genomics doi: 10.1016/j.ygeno.2007.02.005 contributor: fullname: Bibikova – volume: 39 start-page: 41 year: 2007 ident: 2022060712151366500_bib4 article-title: Integrative molecular concept modeling of prostate cancer progression publication-title: Nat Genet doi: 10.1038/ng1935 contributor: fullname: Tomlins – volume: 1840 start-page: 2589 year: 2014 ident: 2022060712151366500_bib40 article-title: Matrikines from basement membrane collagens: a new anti-cancer strategy publication-title: Biochim Biophys Acta doi: 10.1016/j.bbagen.2013.12.029 contributor: fullname: Monboisse – volume: 278 start-page: 37632 year: 2003 ident: 2022060712151366500_bib44 article-title: Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells publication-title: J Biol Chem doi: 10.1074/jbc.M307339200 contributor: fullname: Panka – start-page: 321 volume-title: Biochemistry of collagens, laminins and elastin: structure, function and biomarkers year: 2019 ident: 2022060712151366500_bib43 article-title: The signals of the extracellular doi: 10.1016/B978-0-12-817068-7.00033-1 contributor: fullname: Reese-Petersen – volume: 67 start-page: 157 year: 2015 ident: 2022060712151366500_bib1 article-title: Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study publication-title: Eur Urol doi: 10.1016/j.eururo.2014.01.020 contributor: fullname: Joniau – volume: 30 start-page: 413 year: 2012 ident: 2022060712151366500_bib10 article-title: Absolute quantification of somatic DNA alterations in human cancer publication-title: Nat Biotechnol doi: 10.1038/nbt.2203 contributor: fullname: Carter – volume: 2 start-page: 401 year: 2012 ident: 2022060712151366500_bib22 article-title: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0095 contributor: fullname: Cerami – volume: 95 start-page: 340 year: 1982 ident: 2022060712151366500_bib39 article-title: Localization of type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of basement membranes publication-title: J Cell Biol doi: 10.1083/jcb.95.1.340 contributor: fullname: Laurie – volume: 6 start-page: pl1 year: 2014 ident: 2022060712151366500_bib21 article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal complementary data sources and analysis options publication-title: Sci Signal contributor: fullname: Gao – volume: 45 start-page: 663 year: 2018 ident: 2022060712151366500_bib23 article-title: EMT in metastasis: Finding the right balance publication-title: Dev Cell doi: 10.1016/j.devcel.2018.05.033 contributor: fullname: Lo – volume: 181 start-page: 1585 year: 2012 ident: 2022060712151366500_bib51 article-title: A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression publication-title: Am J Pathol doi: 10.1016/j.ajpath.2012.08.005 contributor: fullname: Agell – volume: 60 start-page: 2520 year: 2000 ident: 2022060712151366500_bib41 article-title: Anti-angiogenic cues from vascular basement membrane collagen publication-title: Cancer Res contributor: fullname: Colorado – volume: 108 start-page: 163 year: 2017 ident: 2022060712151366500_bib9 article-title: Antizyme inhibitor 1: a potential carcinogenic molecule publication-title: Cancer Sci doi: 10.1111/cas.13122 contributor: fullname: Qiu |
SSID | ssj0020176 |
Score | 2.4342391 |
Snippet | Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 527 |
SubjectTerms | Case-Control Studies Cell Line, Tumor Gene Expression Regulation, Neoplastic Humans Male Prostate Prostatic Neoplasms - genetics Retrospective Studies Transcriptome |
Title | Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35082164 https://search.proquest.com/docview/2623325801 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIhAXBMurvGQkblVKXk6d46oUlkfQCu2ivVmO47AVIkFtiti98N_4ZczEjpPCglguUeW248jzZTzjfDNDyFNfsrhgWns5TxMMUFJPYjf3MNKqyMsZ120Xhexdsn8Uvz5mx6PRjwFradPkU3V2bl7J_2gVxkCvmCV7Ac06oTAAn0G_cAUNw_WfdLxXNcuz089IfzxZ5vBsriYBLFjbXV6vJxmW3_-EbuTim-W7GurxojpBZa9brzPTjcS0IuTI1w2Sh6x_-rENxZFZdGBLUhxgigiInszx76uhY5t1bXaRRgbfTWwVIXfa_EEi7bYCMNXamOABN8mwfk25g7fLtdsqXuqv0iYVbf8aqfgKj5INNU0uh6cXEPj2pBdrcOPAwxp2Zj-yYwzPTk1CdGelQ3-AxnhgcpmpLWB3b2bKaP2-MTBMdnCzTbP5ey9EMplpKrhdiPuXDdLRFtuAiXGBYgSKESBGhIFAMZfIZSzGiP0bnr9644J-sHhthls3s80iAzHPzr2bbf_oD0FP6_wc3iDXbdRC9wwEb5KRrnbJFdPH9HSXXM0sQ-MW-d5hkjpM0oA6TFKHSdpjkgImaYdJCpikPSapwyStS9pjklpM0g6T1GDyNjl6sTic73u2yYenIpY0XoJvpmdcpXmicvBemV-AS1-qYgaLoZlSqsT6SGGR-mg3JPizsuDgZEYphMaxH90hO1Vd6XuEFlrxIlYQgkRlLJlOZ6VmUuYc9nOuuByTabe04ou5SfFXlY7Jk04BAqwuvkqTla43axFC1BCFDNy7MblrNONERhDzhEES37_odA_Itf4ReUh2mtVGPwKXt8kft5j6CTwZqXc |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antizyme+Inhibitor+1+Regulates+Matrikine+Expression+and+Enhances+the+Metastatic+Potential+of+Aggressive+Primary+Prostate+Cancer&rft.jtitle=Molecular+cancer+research&rft.au=Van+den+Broeck%2C+Thomas&rft.au=Moris%2C+Lisa&rft.au=Gevaert%2C+Thomas&rft.au=Davicioni%2C+Elai&rft.date=2022-04-01&rft.issn=1541-7786&rft.eissn=1557-3125&rft.volume=20&rft.issue=4&rft.spage=527&rft.epage=541&rft_id=info:doi/10.1158%2F1541-7786.MCR-21-0388&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1541_7786_MCR_21_0388 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1541-7786&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1541-7786&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1541-7786&client=summon |